Japanese National RegistryPKD(JRP)
Not Applicable
- Conditions
- autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease
- Registration Number
- JPRN-jRCT1030230618
- Lead Sponsor
- Muto Satoru
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 1100
Inclusion Criteria
Patients with ADPKD and ARPKD are diagnosed according to the Japanese PKD guideline criteria, or genetic information. For the ADPKD cohort, patients with an eGFR more than 15.0 will be included.
Exclusion Criteria
Exclusion criteria include: history of kidney transplantation, active cancer, cancer treatment within last 5 years, or participation in a PKD-related clinical trial. If pathological or genetic examinations reveal that a patient has a type of PKD other than ADPKD or ARPKD, they will be excluded from the study, even if they have already enrolled.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end point from the JRP is kidney composite events, including kidney replacement therapy (hemodialysis, peritoneal dialysis and kidney transplantation), and a 50% decline in eGFR.
- Secondary Outcome Measures
Name Time Method Subsequent end points for patients with ADPKD include: annual rate of change in TKV, annual rate of change in eGFR, PROs, hospitalization, infection, CVD events, and all-cause mortality. <br>Subsequent end points for patients with ARPKD patients include: liver transplantation, all-cause mortality, intellectual disability, and schooling and employment status.